Get 40% Off
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

What's In Store For Molina Healthcare (MOH) Q3 Earnings?

Published 10/28/2019, 12:06 AM
Updated 07/09/2023, 06:31 AM
COR
-
ACHC
-
MOH
-
MD
-

Molina Healthcare, Inc (NYSE:MOH) is scheduled to report third-quarter 2019 results on Oct 29.

The Zacks Consensus Estimate for earnings is pegged at $2.71, indicating a 0.4% dip from the year-ago reported figure. The consensus mark for total revenues stands at $4.1 billion, suggesting a 12.2% drop from the prior-year reported number.

In the last reported quarter, the company delivered adjusted earnings of $3.11, beating the Zacks Consensus Estimate by 21.5%. Moreover, the bottom line improved 38% year over year, mainly on lower expenses and accretion from Meridian buyout.

Its surprise history is impressive, beating estimates in all the trailing four quarters, the average being 66.9%.

What to Expect for Q3 Earnings

The company expects third-quarter results to reflect numbers little less than half the earnings for the second half of the year, mainly due to investment made to improve profits.

Softer revenues are likely to have dampened its overall performance as well.
Molina Healthcare’s top-line is likely to have witnessed a decline due to lower Medicaid membership and loss of contracts.

Nonetheless, we expect that the company might have retained the growth momentum in its marketplace business from the second quarter of 2019.

The company’s medical costs are expected to have been stable as well.

Molina Healthcare is likely to have benefited from attractive cash-flow generation in the third quarter owing to its solid balance sheet.

The company is expected to have incurred high interest expenses in the third quarter of 2019, which increases its financial risk.

What the Quantitative Model Predicts

Our proven model predicts an earnings beat for Molina Healthcare this reporting cycle. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.

Earnings ESP: Molina Healthcare has an Earnings ESP of +0.92%. This is because the Most Accurate Estimate is pegged at $2.73, higher than the Zacks Consensus Estimate of $2.71. You can see the complete list of today’s Zacks #1 Rank stocks here.

Molina Healthcare, Inc Price and EPS Surprise

Molina Healthcare, Inc Price and EPS Surprise

Molina Healthcare, Inc price-eps-surprise | Molina Healthcare, Inc Quote

Zacks Rank: Molina Healthcare carries a Zacks Rank #3. Further, a positive ESP increases the odds of a positive surprise this earnings season.

Other Stocks to Consider

Some other stocks worth considering from the medical sector with the perfect mix of elements to also surpass estimates in the next releases are as follows:

Mednax, Inc (NYSE:MD) is set to report third-quarter earnings on Nov 1. The stock has a Zacks Rank of 3 and an Earnings ESP of +1.10%.

AmerisourceBergen Corporation (NYSE:ABC) is slated to announce third-quarter earnings on Nov 7. The stock has an Earnings ESP of +0.55% and is Zacks #3 Ranked.

Acadia Healthcare Company, Inc. (NASDAQ:ACHC) is set to report third-quarter earnings on Nov 5. The stock is Zacks #3 Ranked and an Earnings ESP of +1.34%.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>



Molina Healthcare, Inc (MOH): Free Stock Analysis Report

Acadia Healthcare Company, Inc. (ACHC): Free Stock Analysis Report

Mednax, Inc (MD): Free Stock Analysis Report

AmerisourceBergen Corporation (ABC): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.